智力障碍男性的前列腺癌诊疗与生存:基于人群的队列研究
结果显示ID组更常出现提示PC的症状,但PSA检测、转诊、活检及PC诊断均较少,确诊后PC死亡风险为对照组的2.11倍。
要点
- ID男性出现提示前列腺癌症状更频繁(IRR 1.35),但90天内接受PSA检测的比例更低(RR 0.66)。
- PSA升高后,ID组转诊(RR 0.83)、活检(RR 0.54)及前列腺癌诊断(RR 0.51)均显著少于对照组。
- ID组确诊后前列腺癌死亡风险是对照组的2.11倍(HR 2.11,95%CI 1.64-2.73)。
核心结论
- 智力障碍男性在前列腺癌诊疗路径从症状评估到确诊后生存各环节均存在差异,需针对性干预。
研究设计与样本
- 采用泊松回归和Cox回归估计 incidence rate ratio(IRR)、risk ratio(RR)及 hazard ratio(HR)及其95%置信区间。
主要发现
- ID组更常出现提示前列腺癌的症状(IRR 1.35,95%CI 1.28-1.43),但90天内PSA检测率更低(RR 0.66,95%CI 0.63-0.70)。
- PSA升高后,ID组转诊(RR 0.83,95%CI 0.72-0.96)、活检(RR 0.54,95%CI 0.41-0.71)及前列腺癌诊断(RR 0.51,95%CI 0.41-0.65)均更少。
- ID组更常在死亡当日确诊(RR 5.96,95%CI 2.70-11.77),Gleason评分缺失更常见(RR 1.61,95%CI 1.27-2.01),初诊即为转移性前列腺癌更常见(RR 1.79,95%CI 1.15-2.77)。
- 在有Gleason评分的患者中,ID组与对照组的临床显著前列腺癌(Gleason≥7)比例相当,但非转移性前列腺癌接受根治性治疗的比例略低(RR 0.73,95%CI 0.51-1.00)。
- ID组确诊后前列腺癌死亡风险为对照组的2.11倍(HR 2.11,95%CI 1.64-2.73)。
临床怎么用
- 对智力障碍男性出现提示前列腺癌症状时应提高警惕,并主动评估PSA检测与转诊指征。
- PSA升高后应确保公平的活检与诊断机会,避免因智力障碍而减少侵入性检查。
- 确诊后应关注根治性治疗的可及性及生存差异,必要时进行个体化支持。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Intellectual disability (ID) is increasingly recognised as a hidden driver of cancer mortality. However, evidence on prostate cancer (PC) care in this population is limited. METHODS: The study population comprised 29 554 men with an ID and 518 739 comparators from the Clinical Practice Research Datalink Aurum database, which is linked to hospital, mortality, and cancer registry data. Poisson and Cox regression analyses were used to estimate incidence rate ratios (IRRs), risk ratios (RRs), and hazard ratios (HRs) with 95% confidence intervals (CIs) for outcomes related to PC presentation, diagnosis, treatment, and survival. KEY FINDINGS AND LIMITATIONS: The ID group presented more frequently with symptoms suggestive of PC (IRR 1.35, 95% CI 1.28-1.43) but were less likely to have a prostate-specific antigen (PSA) test within 90 d (RR 0.66, 95% CI 0.63-0.70). Following detection of elevated PSA, the ID group had fewer referrals (RR 0.83, 95% CI 0.72-0.96), biopsies (RR 0.54, 95% CI 0.41-0.71), and PC diagnoses (RR 0.51, 95% CI 0.41-0.65). The ID group were also more likely to be diagnosed on the date of death (RR 5.96, 95% CI 2.70-11.77), have missing Gleason scores (RR 1.61, 95% CI 1.27-2.01), and present with de novo metastatic PC (RR 1.79, 95% CI 1.15-2.77). Among those with Gleason scores, the rate of clinically significant PC (Gleason ≥7) was comparable between the ID and control groups, while receipt of radical treatment for nonmetastatic PC was slightly lower in the ID group (RR 0.73, 95% CI 0.51-1.00). Men with an ID had twofold higher risk of death from PC following diagnosis (HR 2.11, 95% CI 1.64-2.73). CONCLUSIONS AND CLINICAL IMPLICATIONS: Men with an ID face disparities across the PC care pathway from investigation of relevant symptoms to survival after diagnosis. Targeted interventions are needed to address these inequities.
引用
- Kennedy OJ, Chauhan U, Gorman L, et al. Prostate Cancer Care for Men with an Intellectual Disability: A Population-based Cohort Study of Symptoms, Diagnosis, Treatment, and Survival. Eur Urol Oncol. 2027. PMID: 41720694. doi:10.1016/j.euo.2026.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。